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Background and purpose: We assessed the causes of death and efﬁcacy of permanent inferior vena cava
(IVC) ﬁlters for preventing new pulmonary embolisms (PE) in Japanese deep vein thrombosis (DVT)
patients with or without PE.
Methods and subjects: We studied the clinical outcomes during the follow-up period of 1 day to 9 years
(median: 18 months; mean: 28 months) in 66 of 72 consecutive patients (44 with acute PE, 27 with
intrapelvic DVT, and 1 with ﬂoating femoral vein thrombosis). Fifty of 66 patients received anticoagulant
therapy after the ﬁlter placement.
Results: Five patients died within 1 month (median 9 days) after the ﬁlter placement: three from recur-
rence of PE, one from cancer, and one from sepsis. Two of the three patients with recurrence of PE had
preexisting intracardiac thrombi in the right atrium or main pulmonary artery before ﬁlter implantation.
Ten patients died from the underlying disease (cancer: 7; brain hemorrhage: 1; amyotrophic lateral scle-
rosis: 1; pneumonia: 1) over 1 month after the ﬁlter placement (median follow-up period: 21 months).
Nonewsymptomatic PE recurrencewas observed over 1month after the ﬁlter placement. The 61patients
with long-term follow-up had no deterioration of DVT, and all the 31 patientswho underwentmulti-slice
computed tomography showed no PE recurrence or ﬁlter thrombus occlusion, fracture, or migration.
Conclusions: Underlying diseases and preexisting intracardiac thrombi may be the determining factors
for the prognosis of DVT patients. Permanent IVC ﬁlters with anticoagulant therapy may be effective for
preventing death from new PE in Japanese DVT patients.
© 2014 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.ntroduction
Pulmonary embolism (PE) is a fatal disease and the infe-
ior vena cava (IVC) ﬁlter has been widely used to prevent
E development in patients with deep vein thrombosis (DVT)
1–8]. The general currently accepted indications for ﬁlter place-
ent include patients with contraindications to anticoagulant
reatment, such as gastrointestinal bleeding, intracranial hemor-
hage, or bleeding complications during antithrombotic treatment,
∗ Corresponding author at: Department of Cardiology, Hiroshima Prefectural
ospital, 1-5-54 Ujina-kanda, Minami-Ku, Hiroshima 734-8530, Japan.
el.: +81 82 254 1818; fax: +81 82 253 8274.
E-mail address: d103150@hiroshima-u.ac.jp (Y. Iwamoto).
ttp://dx.doi.org/10.1016/j.jjcc.2014.01.011
914-5087/© 2014 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.thromboembolism recurrences despite optimal anticoagulation,
and ﬂoating thrombi in the iliac vein [5,6]. IVC ﬁlters have been
used for PE prophylaxis in patients with head injury, trauma, and
pregnancy, and in preoperative DVT patients [9–12]. However,
numerous complications are associated with the use of IVC ﬁlters,
including migration, thrombosis, and IVC perforation, in patients
with long-term use (over 30 days) [13–21]. Filter retrieval is rec-
ommendedonce the riskof PE is reducedandanticoagulant therapy
is no longer contraindicated [22]. However, it is difﬁcult to judge
the risk of PE development following IVC ﬁlter retrieval; thus this
procedure is often not performed at the appropriate time. More-
over, during ﬁlter retrieval, massive PE or injury to the vein may
occur, and this procedure is unsuccessful in 10–20% of the patients
because of ﬁlter adhesion to the vessel wall, technical problems
due to the tilt of the ﬁlter, etc. [23]. A recent Japanese study on
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Table 1
Patient characteristics.
Characteristic Number of patients
Men/women 32/34
Age (years) 65±15
Reasons of ﬁlter
Acute PE+DVT 40
Intrapelvic DVT 25
Floating femoral vein thrombosis 1
Underlying diseases and risk factors
Prolonged bed rest 24
Hematological or coagulation disorder 8
Protein S deﬁciency 5
Antiphospholipid antibody syndrome 1
Essential thrombocythemia 1
Estrogenic drug 1
Postoperative state 6
Posttraumatic state, bone fracture 7
Cancer 14
Cerebrovascular disease 6
Leg varix 3
Pregnancy 1
Nephrotic syndrome 1
Unknown 17
acute Japanese PE patients was 0.8% in patients without shock or
right ventricular overload, 2.7% in patients with right ventricular
overload without shock, and 15.6% in patients with shock [27].
Table 2
Causes of death within 1 month after IVC ﬁlter implantation.
Cause of death Number of patients
Acute PE
Thrombus in the right atrium or main pulmonary
artery before placing the ﬁlter
2
Fresh thrombus in the bilateral main pulmonary
artery
1Y. Iwamoto et al. / Journal o
etrievable extracorporeal IVC ﬁlters also reported complications
ue to IVC ﬁlter removal [24]. After IVC ﬁlter retrieval, DVT relapses
n 4.0% of the patients, and the PE mortality rate following this
rocedure is high (2.6%) [25]. The long-term outcomes may differ
etween Japanese and Western individuals, as Asian individuals
how less thrombogenesis and smaller body size compared to
esterners, whichmay affect ﬁltermigration. In the present study,
e investigated the causes of death and the efﬁcacy of permanent
VC ﬁlters for preventing new PE in Japanese DVT patients at risk
or PE development.
tudy population and methods
We studied 72 consecutive patients who underwent permanent
VC ﬁlter implantation between January 1996 and May 2009 at
iroshima Prefectural Hospital. When a short PE prophylaxis
uration was used in patients with small or non-ﬂoating DVT, we
sed a temporary ﬁlter (Newhaus Protect, Toray Medical, Tokyo,
apan) connected to a tethering catheter; therefore, these patients
ere excluded from the present study. Permanent ﬁlters were
mplanted into 44 acute PE patients, 27 intrapelvic DVT patients,
nd 1 patient with ﬂoating femoral vein thrombosis. The mean age
f the patients was 69 years, and the study included 33 men and
9 women. The underlying diseases or risk factors for DVT were
rolonged bed rest (27 patients), hematological or coagulation dis-
rders (8 patients, including protein S deﬁciency, antiphospholipid
ntibody syndrome, essential thrombocythemia, and estrogenic
rug use), postoperative state (6 patients), posttraumatic state or
one fracture (8 patients), cancer (14 patients), cerebrovascular
isease (6 patients), leg varices (3 patients), pregnancy (1 patient),
nd nephrotic syndrome (1 patient). The following IVC ﬁlters
ere used: Greenﬁeld (3 patients; Boston Scientiﬁc, Natick, MA,
SA), Celsa (19 patients; B. Braun Medical, Bethlehem, PA, USA),
ünther (40 patients; Cook, Bloomington, IN, USA), and OptEase
5 patients; Cordis, Roden, The Netherlands). We were unable
o determine the ﬁlter type used in ﬁve cases. The reasons for
ermanent IVC ﬁlter placement included poor compliance or
high risk of anticoagulant therapy-related complications (16
atients), recurrent venous thromboembolism despite adequate
nticoagulant therapy (9 patients), free-ﬂoating DVT (33 patients),
ecreased cardiac function or severe pulmonary hypertension
8 patients), residual thrombus 2 weeks after temporary IVC ﬁlter
lacement (31 patients), and the presence of a condition associated
ith a high risk of recurrent PE (23 patients). We could not identify
he reason for permanent IVC ﬁlter placement in two cases.
The chart recordswere reviewedand telephone interviewswere
onducted to examine the patient prognosis. We were able to
ollow up in 66 of the 72 patients and examined their clinical
utcomes. Clinical outcomes were examined in 5 patients during
he follow-up period within 1 month, and in 61 patients there
as more than 1-month follow-up period (1 month to 9 years;
edian, 21 months). The underlying diseases of 18 patients were
nknown (Table 1). Anticoagulant therapy was performed in 50 of
he 61 patients, who could receive oral warfarin clinically during
he follow-up period.
Multislice computed tomography (MDCT) was performed in
1 of the 51 surviving patients to investigate PE recurrence, ﬁlter
hrombus occlusion, fracture, and migration.
esultsFive of the 66 patients died within 1 month (1–21
ays, median 9 days) after the IVC ﬁlter placement
The causes of death were acute PE in three cases, cancer in
ne case, and sepsis in one case (Table 2). The acute PE patientsAnticoagulant therapy 50
PE, pulmonary embolism; DVT, deep vein thrombosis.
died on the ﬁrst, third, and eighth days after IVC ﬁlter placement.
The thrombi that caused acute PE were preexisting at the prox-
imal site of the IVC ﬁlter (the right atrium or main pulmonary
artery) in two of these patients prior to IVC ﬁlter implantation.
In the remaining patient, a fresh thrombus in the bilateral main
pulmonary artery was conﬁrmed by autopsy, while there was no
evidence of a central thrombus at the time of ﬁlter placement.
Over 1month after the placement of IVC ﬁlters, 51 of 61 patients
(84%) survived the median follow-up period of 21 months. Ten
patients died and the cause of death was cancer in seven cases,
brain hemorrhage in one case, amyotrophic lateral sclerosis in one
case, and pneumonia in one case. The symptomatic recurrence of
acute PE was none over 1 month after IVC ﬁlter placement (Fig. 1).
Anticoagulant therapy was administered to 50 of the 61 surviving
patients and there were no signs of DVT deterioration. All 31 of the
surviving patients who underwent MDCT revealed no recurrence
of PE or ﬁlter thrombus occlusion, fracture, or migration.
Discussion
In 1027 Japanese medical patients with acute PE, the main
risk factors were a prolonged immobilization, stroke, cancer, and
indwelling central venous catheter, and in-hospital mortality rate
was 23% [26]. Hematological or coagulation disorders were evi-
dent as the other causes in the present study. Mortality among 465Underlying disease
Cancer 1
Sepsis 1
IVC, inferior vena cava; PE, pulmonary embolism.
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vena cava ﬁlter placement: do physicians comply with guidelines. J Vasc Interv
Radiol 2012;23:989–95.
[7] Van Ha TG, Chien AS, Funaki BS, Lorenz J, Piano G, Shen M, Leef J. Use of retriev-ig. 1. Causes of death over one month (median 21 months) after implanting IVC
lter in 61 patients with proximal deep vein thrombosis. There was no new symp-
omatic PE resulting in death. IVC, inferior vena cava; PE, pulmonary embolism.
PE requires timely recognition and rapid therapy. IVC ﬁlters are
ighly effective in preventing PE [1–12]. Weekend admissions for
E treatment were associated with higher mortality rates (odds
atio: 1.19) than weekday admissions due to delayed IVC ﬁlter
lacement [28]. In Japanese patients, Ishikura et al. [29] demon-
trated the trapped thrombus within the Günther ﬁlter in 3/13
atients and Yamagami et al. [30] also demonstrated the efﬁcacy
f Günther ﬁlters, showing trapped thrombus in the ﬁlters in 54%
f the 37 sessions by repeated venocavography.
However, a permanent ﬁlter placement may not always pre-
ent PE in all DVT patients, and the incidence of post-ﬁlter PE
s 0.5–15% [4,31,7], although this prevalence was 1.7% in a large
atient population (6834 patients from37 studies) during a follow-
p period of 1.74±2.36 years [3]. The PREPIC study, a randomized
-year follow-up study after ﬁlter placement, has shown that ﬁl-
er placement reduces symptomatic PE (6.2%) as compared with a
on-ﬁlter group (15.1%) [32]. In the present study, only one patient,
xcluding preexisting intracardiac thrombus cases, died from new
E 8 days after IVC ﬁlter placement. We showed that a permanent
VC ﬁlter placement was quite effective (100%) for more than 1
onth after placement for preventing death due to new PE at risk
f PE development. The prevalence of post-ﬁlter PE may depend
n the presence or absence of anticoagulant therapy. In the PREPIC
tudy, vitamin K antagonists were prescribed as a rule for 3 months
nd only 35% of patients received anticoagulant therapy over the
ntire 8-year study. In our study, 82% of the patients received anti-
oagulant therapy after IVC ﬁlter placement.
Moreover, in the PREPIC study, the DVT increased in the ﬁlter
roup (35.7%) as compared with the non-ﬁlter group (27.5%) [32].
owever, we did not ﬁnd deterioration of DVT in the present study.
VT after ﬁlter placement may also be affected by the presence or
bsenceof anticoagulant therapy. The incidenceof theﬁlter-related
hrombus and estimated volume are highest during the 0–30-day
well interval (8.0%), and the ﬁlter-related thrombus interval is
nversely related to the dwell time (correlation coefﬁcient, −0.86)
33]. Thus, the size and extent of thrombus may generally decrease
fter theplacement of theﬁlter for PE. Theﬁlter shouldbe retrieved,
hen the DVT is not vulnerable and the possibility of PE recur-
ence is low. It is sure that the incidence of PE recurrence after IVC
lter retrieval is 2–8% [25,34] and the mortality rate is 2.6% [25].
he rate of successful ﬁlter retrieval is quite high (>90%) even at
months after implantation [12]. Therefore, when we are afraid
f DVT vulnerability and the possibility of PE, we are compelled
o postpone the retrieval of the ﬁlter. In those cases, we shouldiology 64 (2014) 308–311
keep anticoagulant therapy, if possible, for preventing new PE or
DVT deterioration. Numerous complications are associated with
the long-term use of IVC ﬁlters (over 30 days), including migra-
tion, thrombosis, and IVC perforation [13–21]. However, in our
small number of cases, we did not experience major ﬁlter-related
troubles during long-term indwelling.
The incidence of post-ﬁlter PE is higher in cancer patients (5.2%)
and is associated with a poor prognosis [13,35,36]. The long-term
prognosis of the patients with acute PE may not depend on the
recurrence of PE alone. In the present study, the cause of death
after ﬁlter implantation was an underlying disease in 12 patients
(80%) and 8 of these patients (67%) had cancer, although post-ﬁlter
PE was not evident. Thus, the underlying diseases may cause DVT
and PE and may also determine the patient prognosis.
Limitations
This study was performed in a single center. The data were
observational and not randomized. This was not a comparative
study between patientswith andwithout permanent IVC ﬁlter, and
was merely an observational study about patients with permanent
IVC ﬁlter with 82% on anticoagulation therapy. The case number
was small and follow-up period was not so long. Therefore, further
randomized comparative studies are needed on the effectiveness
of permanent IVC ﬁlter with or without anticoagulation therapy.
Conclusions
Five of the sixty-six follow-up patients died within 1 month
after ﬁlter placement, and preexisting intracardiac thrombus and
underlying disease were important causes of death. Over 1 month
after ﬁlter placement, 51 (84%) of 61 patients survived the median
follow-up period of 21 months, receiving anticoagulant therapy in
82% of cases. Underlying diseases, particularly cancer, may be the
most important determining factors for causes of death. No acute
symptomatic PE was evident over 1 month after ﬁlter placement.
Excluding intracardiac thrombus patients, permanent IVC ﬁlters
with anticoagulant therapy may be effective for preventing death
fromnewPEwithoutmajor complications in JapaneseDVTpatients
with a high risk of PE development.
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